-
Sanofi And Regeneron Announce Patient Enrollment In Two Phase 3 Trials With Sarilumab In Rheumatoid Arthritis
5/15/2013
|
-
Barclays Capital Is Raising Regeneron Pharmaceuticals (REGN) FY14 Estimate To 7.87 From 6.76
5/6/2013
|
-
Barclays Capital Is Increasing Regeneron Pharmaceuticals (REGN) FY13 Estimate To 8.41 From 7.42
5/6/2013
|
|
|
|
|
|
|
|
|
|
|
-
Regeneron Pharmaceuticals Q1 EPS Surges To $0.90 From $0.11 Last Year
5/3/2013
|
-
Regeneron Purchases Full Rights To Two Novel Ophthalmology Development Programs
5/3/2013
|